AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01283-06v1
51/5/1840    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Norén, T.
Right arrow Articles by Unemo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Norén, T.
Right arrow Articles by Unemo, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2007, p. 1840-1843, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01283-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Mutations in fusA Associated with Posttherapy Fusidic Acid Resistance in Clostridium difficile{triangledown}

T. Norén,1* T. Åkerlund,4 M. Wullt,3 L. G. Burman,4 and M. Unemo2

Department of Infectious Diseases,1 Department of Clinical Microbiology,2 Örebro University Hospital, Örebro, Department of Clinical Sciences, Malmö, Lund University, Lund,3 Swedish Institute for Infectious Disease Control, Solna, Sweden4

Received 13 October 2006/ Returned for modification 10 November 2006/ Accepted 2 February 2007

In silico, we identified fusA (2,067 bp) in Clostridium difficile 630. Sequencing of fusA in posttherapy fusidic acid-resistant C. difficile isolates from 12 patients with C. difficile-associated diarrhea (CDAD) identified fusA mutations, one or two nonsynonymous substitutions, or in one case a deletion of one codon associated with resistance. Five of these mutations have previously been described in fusA of fusidic acid-resistant Staphylococcus aureus, but seven were novel fusA mutations. Fusidic acid monotherapy for CDAD seemed to rapidly select conserved resistant mutants.


* Corresponding author. Mailing address: Department of Infectious Diseases, Örebro University Hospital, SE-701 85 Örebro, Sweden. Phone: 46-19-602 10 42. Fax: 46-19-18 48 55. E-mail: torbjorn.noren{at}orebroll.se

{triangledown} Published ahead of print on 16 February 2007.


Antimicrobial Agents and Chemotherapy, May 2007, p. 1840-1843, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.01283-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.